Skip to content

Clinical trials

Child Development Disorders, Pervasive trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Child Development Disorders, Pervasive Phase: Not applicable Clear all

51 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20031
20041
20073
20081
20091
20104
20111
20121
20136
20142
20152
20163
20173
20182
20191
20203
20213
20221
20231
20242
20254
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed34
Terminated4
Unknown status4
Recruiting4
Not yet recruiting2
Withdrawn1
Enrolling by invitation1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Yale University5
National Taiwan University Hospital3
Emory University2
Federal University of Paraíba2
Massachusetts General Hospital2
The Hong Kong Polytechnic University2
University of California, Los Angeles2
University of Pittsburgh2
Université de Montréal2
Ataturk University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Child Development Disorders, Pervasive51
Autistic Disorder30
Autism Spectrum Disorder29
Asperger Syndrome13
Attention Deficit Disorder with Hyperactivity3
Anxiety Disorders2
Sensation Disorders2
Alzheimer Disease1
Brain Injuries, Traumatic1
CADASIL1

Trials

Showing 51 to 51 of 51. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.